http://www.reportbuyer.com/rss.htmlIn this section you will find information products, including market research reports, on Cardiovascular Diseases. More specifically, Circulatory System Angina, Thrombosis and Acute Coronary Syndromes.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/thrombopoiesis_stimulating_agents_tpo.htmlThe Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO, IL-11) as of November 2009 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development. The product portfolio and R&D pipeline includes six products on the market, further eight clinical stage and further ten preclinical new molecules in various indications from the product categories antibody, protein, peptide and small molecule (NCE). Thrombopoiesis stimulating agents are under evaluation for treatment of idiopathic thrombocytopenic purpura (ITP) and for prevention of severe thrombocytopenia induced by chemotherapy. 34b4426402e2b89d736a802f0a8c6599Wed, 11 Nov 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/global_cardiac_rhythm_management_crm_market_report_2009_edition.htmlThe increasing number of cardiovascular diseases and sudden cardiac deaths are driving the growth of cardiac rhythm management devices market. The CRM market broadly consists of implantable cardioverter-defibrillators (ICD) and pacemakers. The CRM market registered double digit growth rates in early 90s but several product recalls during early 2000s led to a significant decline in the utilization of ICDs. d1ccecd82e16ef9a5daf369359c7f446Sat, 08 Aug 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/global_cardiovascular_drugs_market_2009_2024.htmlExpanding Patent Populations and Disease Prevalence - Our New Pharma Report Highlights Sales Opportunities Cardiovascular disorders are leading causes of death worldwide. Cardiovascular therapeutics form a central part of the global pharmaceutical market, with a wide range of treatments, including leading blockbusters. As the patient population grows and cardiovascular diseases become more prevalent, cardiovascular drugs have the potential for continued sales growth in both mature and emerging markets. 1daf4538b29ee0330325ad3c96911bebSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/japan_markets_peripheral_vascular_devices.htmlIn 2008, the Japanese market for peripheral vascular devices was valued at just over $266 million, representing growth of nearly 7% over 2007. Japan is the second-largest market for peripheral vascular devices in the world due to its aging population and universal healthcare coverage. This market includes peripheral stents, PTA balloon catheters, stent-grafts, surgical grafts, embolic protection, IVUS catheters, inferior vena cava filters, potential atherectomy, interventional and diagnostic catheters, interventional and diagnostic guidewires, introducer sheaths and vascular closure devices. 444ec6e4c84295fcedc587b4d7eeb1d5Tue, 05 May 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/u_s_market_interventional_cardiology_2009.htmlIn 2008, the U. S. market for interventional cardiology was valued at $US 4. 6 billion. This value represents drug-eluting stents, PTCA balloons, coronary closure devices, bare-metal stents, embolic protection devices, interventional guidewires, diagnostic catheters, intravascular ultrasound (IVUS) catheters, and interventional catheters. c5fecefebd53ebfdb048053aace8acdbSat, 04 Apr 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/investfrost_chemicals_u_s_heart_health_ingredients_market.htmlIncreasing Health Consciousness among Consumers Provides Positive Momentum for the U. S. Heart Health Ingredients Market The American Heart Association has revealed that approximately 80. 527086315c779c47cb526ccead770281Sat, 04 Apr 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/overview_general_hospital_consumables_cardiovascular_products_market_sri_lanka.htmlFuture Prospects for the General Hospital Consumables and Cardiovascular Products Market in Sri Lanka Look Promising Driven by Superior Healthcare Infrastructure General hospital consumables or disposable medical device and cardiovascular products are a vital aspect of the total medical device industry. The hospital disposable market has been growing steadily over the last few years with good growth prospects. Disposable needles, syringes, IV catheters, stents, and angiographic catheters have the highest demand in the disposable and cardiovascular medical device markets. 745658690f5812487d8d96c8ae79d87dTue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/investfrost_chemicals_european_heart_health_ingredients_market.htmlThe European Food and Beverage Industry Introduces Innovative Healthy Food Products to Cater to the Growing Consumer Trend towards Health Foods The trend towards a healthy life and longer life expectancy is gaining impetus, thanks to extensive media focus on heart health ingredients. Consumers are preferring foods that are not just tasty, but also healthy. Therefore, foods and beverage manufactures have begun to introduce innovative food products, based on heart health ingredients. 77edb4d0bfaeb2b9254dd00c28f038a2Tue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/cardiovascular_business_digest_u_s_heart_valve_market.htmlThis research provides insight into the various aspects such as market dynamics, revenue forecasts, competitive analysis etc pertaining to the U. S. heart valve market. 284bd8c2422cefe5b619fdb2c36f29e0Mon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/china_hypertension_drug_market_report_1.htmlEpidemiology data indicate that there are about 200 million hypertension patients in China. Every year there are 2 million newly added patients with stroke, 500,000 newly added patients with myocardial infarction and 3 million patients died of cardiovascular and cerebrovascular diseases. Annual costs for the treatment of cardiovascular and cerebrovascular diseases in China are about RMB 130 billion (USD 18 billion), among which RMB 36. 420889089f9abff0ed3e14ea8ec2ed8aMon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/commercial_insight_cardiovascular_metabolic_market_overview_diabetes_fore_generics_hit_primary_care_markets.htmlIntroductionDatamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0. 9% in the seven major markets. c7071a2a88f32c194082a93d2e185d42Mon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/cardiovascular_market_outlook_2013.htmlThe cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, such as the current generic threat for dyslipidemics and competition from novel therapies in thrombosis. Leading products in these sub-therapy areas have proven to be significant growth drivers for Big Pharma, such as Pfizer's Lipitor, Sanofi's Plavix and Lovenox, and Amgen's Aranesp. fd296af035d1b2f46331331452594ef7Thu, 01 Jan 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/european_market_cadiac_rhythm_management_electrophysiology_ablation_devices_2009_15_countries.htmlIn 2008, the market for cardiac rhythm management, electrophysiology, and ablation devices was valued at nearly €2. 2 billion ($3. 4 billion), an 11. 727c41c0eed603b85e0fa42adad9de76Thu, 01 Jan 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/stem_cells_cardiovascular_disease_2009_market_report.htmlThis is the latest and most up-to-date Worldwide Stem Cells Market Report from Select Biosciences, based on our continual industry coverage. Select Biosciences industry coverage in this report focuses on the technical, market, and clinical trials aspects of stem cells being developed for addressing the opportunities in the cardio and vascular disease spaces. Major emphasis is placed on the various clinical applications of mesenchymal stem cells (MSCs)-a key stem cell lineage of paramount importance for regenerative medicine. e4a2a8d6e684d7fbf76f7982c7174017Thu, 01 Jan 2009 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/cardiovascular_market_digest_u_s_crm_market.htmlThis research provides insight into the various aspects such as market dynamics, revenue forecasts, competitive analysis etc pertaining to the cardiac rhythm management (CRM) market. . 84a0410609f237bb3bdec7287e936cf8Fri, 12 Dec 2008 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/u_s_cardiovascular_business_digest_drug_eluting_stent_market.htmlThis research provides insight into the various aspects such as market dynamics, revenue forecasts, competitive analysis etc pertaining to the drug eluting stent market. . 41299abd6674db0fa12be2bba53b7d81Tue, 09 Sep 2008 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/european_markets_vascular_access_devices_2008_15_countries.htmlVascular access devices primarily consist of disposable devices. They range from devices that can be high volume and low cost (peripheral intravenous catheters (PIVCs)), to devices that are relatively low volume and high cost (implantable ports). PIVCs represent the market segment with the largest value, due to the sheer amount of units sold. a18ce783b12c4c4a0cf727bc778aac7cTue, 09 Sep 2008 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/italian_market_vascular_access_devices_2008.htmlThe Italian market for vascular access devices was the fourth largest in Europe in 2007. Over the forecast period, this market is expected to grow more rapidly than any other European country. This can be attributed to the recent growth of the port and PICC market. 690ac792a3840f312d40439bf757c685Tue, 09 Sep 2008 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/swiss_market_vascular_access_devices_2008.htmlSwitzerland's extremely high GDP per capita along with higher average selling prices has led to a strong market for vascular access devices. The market is predicted to continue growing with the safety PIVC segment seeing the highest growth rate over the forecast period. . 4fc3e7ba0198d63148fdef3897da6552Tue, 09 Sep 2008 12:00:00 GBPharma & Healthcare/Cardiovascularhttp://www.reportbuyer.com/pharma_healthcare/cardiovascular/scandinavian_market_vascular_access_devices_2008.htmlThe Scandinavian market for vascular access devices, which includes Sweden, Finland, Denmark and Norway, was the sixth largest in Europe and saw the largest growth rate of any European market in 2007. Sweden represented the largest market in Scandianavia due to its large population and that many companies initially promote new products in Sweden before they spread to the rest of Scandinavia. The market is predicted to continue growing with the PICC segment growing the fastest. 2d3e19b89f3034fc46b51121b2745d35Tue, 09 Sep 2008 12:00:00 GBPharma & Healthcare/Cardiovascular